Here, we investigated whether the resistance to sunitinib (Sun), the standard treatment for metastatic ccRCC, is due to up‐regulation of programmed death ligand 1 (PD‐L1) by the transcription factor E3 (TFE3). This evidence concerns the gene TFE3 and nonpapillary renal cell carcinoma.